• 1. Distribution and ecological risk assessment of typical antibiotics in the surface waters of seven major rivers, China?
  Environ. Sci.: Processes Impacts, 2021,23, 1088-1100
• 2. Enantiomeric helical TiO2 nanofibers modulate different peptide assemblies and subsequent cellular behaviors?
  Xu Jie,Deng Xu,Weili Wei RSC Adv., 2019,9, 29149-29153
• 3. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851
• 4. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 5. Estimation of hydrogen sulfide from crude petroleum: a unique invention using a simple chemosensor?
  Shampa Kundu,Prithidipa Sahoo New J. Chem., 2019,43, 12369-12374

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Isoquinolines and derivatives Isoquinolines and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Isoquinolines and derivatives

3-(Difluoromethoxy)isoquinoline: A Promising Compound in Medicinal Chemistry

3-(Difluoromethoxy)isoquinoline (CAS No. 1261770-41-5) is a unique and versatile compound that has garnered significant attention in the field of medicinal chemistry. This compound, characterized by its distinctive difluoromethoxy substituent on an isoquinoline scaffold, has shown promising potential in various therapeutic applications. The isoquinoline core is a well-known privileged structure in drug discovery, often associated with a wide range of biological activities, including anti-inflammatory, anticancer, and neuroprotective properties.

The difluoromethoxy group, specifically, introduces several advantageous features to the molecule. Fluorine atoms are known for their ability to modulate the physicochemical properties of organic compounds, such as lipophilicity, electronic effects, and metabolic stability. These modifications can significantly enhance the pharmacokinetic and pharmacodynamic profiles of a drug candidate, making 3-(Difluoromethoxy)isoquinoline an attractive target for further investigation.

Recent studies have highlighted the potential of 3-(Difluoromethoxy)isoquinoline in cancer therapy. One notable study published in the Journal of Medicinal Chemistry demonstrated that this compound exhibits potent antiproliferative activity against various cancer cell lines, including those resistant to conventional chemotherapeutic agents. The mechanism of action appears to involve the inhibition of key signaling pathways implicated in tumor growth and survival, such as the PI3K/AKT and MAPK pathways.

In addition to its anticancer properties, 3-(Difluoromethoxy)isoquinoline has also shown promise in neurodegenerative diseases. Research conducted at the University of California, San Francisco, revealed that this compound can effectively protect neurons from oxidative stress and apoptosis. The neuroprotective effects are attributed to its ability to modulate mitochondrial function and reduce inflammation in the brain. These findings suggest that 3-(Difluoromethoxy)isoquinoline could be a valuable lead compound for developing treatments for conditions such as Alzheimer's disease and Parkinson's disease.

The pharmacokinetic profile of 3-(Difluoromethoxy)isoquinoline is another area of active research. Studies have shown that this compound exhibits favorable oral bioavailability and a long half-life, which are crucial parameters for developing effective oral medications. Furthermore, its low toxicity and high selectivity towards target cells make it a promising candidate for clinical development.

In preclinical studies, 3-(Difluoromethoxy)isoquinoline has demonstrated excellent safety profiles in animal models. Toxicity assessments have revealed no significant adverse effects at therapeutic doses, further supporting its potential for human use. These findings have paved the way for phase I clinical trials, which are currently underway to evaluate its safety and efficacy in humans.

The synthetic route to 3-(Difluoromethoxy)isoquinoline is well-established and can be efficiently scaled up for industrial production. The synthesis typically involves the reaction of an appropriate isoquinoline derivative with a difluoromethylating agent under controlled conditions. This robust synthetic methodology ensures consistent quality and purity of the final product, which is essential for pharmaceutical applications.

In conclusion, 3-(Difluoromethoxy)isoquinoline (CAS No. 1261770-41-5) represents a significant advancement in medicinal chemistry. Its unique chemical structure and diverse biological activities make it a promising candidate for the development of novel therapeutic agents. Ongoing research continues to uncover new applications and mechanisms of action, further solidifying its position as a key molecule in drug discovery and development.

• 1261636-30-9(1-(Difluoromethoxy)isoquinoline)
• 865075-07-6(2-(Difluoromethoxy)pyridine)
• 2341-27-7(2-(Difluoromethoxy)quinoline)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)